The medical technology company's flat year-over-year revenue growth doesn't tell the full story.
Investors really like the company's sneak peek at its Q4 results, which are scheduled to be officially announced next month.
Big news could be on the way.
The healthcare technology company topped Wall Street estimates on both its top and bottom lines in the third quarter.
The biotech's biggest shareholder just made a move that rattled Karuna's other shareholders.
Investors are reacting negatively to the biotech's public stock offering.
The two politicians from different parties are united on at least one front: their opposition to legalizing pot.
Yesterday's euphoria that a virus scare could boost the biotech's fortunes has given way to a more realistic assessment of what's going on.
The healthcare giant delivered a solid quarterly performance yet again, with sales growth in all of its segments.
This beaten-down marijuana stock is a lightning rod among investors.
Opinions vary considerably.
Worries about the spread of a virus in China are driving the biotech's shares higher.
The online pet pharmacy topped analysts' earnings estimates but missed on the top line.
Concern about a new virus in China is providing a big catalyst for this biotech.
The big Canadian cannabis producer won't launch its new beverage products on time. Is it a big deal or nothing to worry about?
There's good news and there's bad news.
The cannabis-focused biotech's presentation at the J.P. Morgan Healthcare Conference was eye-opening.
And it could happen in five years or less.
These stocks skyrocketed during healthcare's biggest event of the year -- the J.P. Morgan Healthcare Conference.
Which stock wins in a matchup between these two healthcare siblings?